Merus Labs International Inc (TSE:MSL) (NASDAQ:MSLI) had its target price upped by equities research analysts at Scotiabank from C$1.25 to C$1.65 in a note issued to investors on Friday, May 12th. The brokerage currently has a “sector perform” rating on the specialty pharmaceutical company’s stock. Scotiabank’s price objective would suggest a potential upside of 1.23% from the stock’s current price.
A number of other research analysts have also recently commented on MSL. CIBC reduced their target price on Merus Labs International from C$1.50 to C$1.40 in a research note on Wednesday, February 15th. TD Securities lowered their price objective on shares of Merus Labs International from C$3.00 to C$1.65 and set a “tender” rating for the company in a report on Friday, May 12th. Finally, Bloom Burton restated a “hold” rating on shares of Merus Labs International in a report on Monday, February 13th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of C$1.99.
Shares of Merus Labs International (TSE MSL) traded up 0.62% during midday trading on Friday, hitting $1.63. The stock had a trading volume of 82,920 shares. The firm’s 50-day moving average is $1.47 and its 200 day moving average is $1.23. Merus Labs International has a one year low of $0.95 and a one year high of $1.76. The company’s market capitalization is $191.29 million.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.com-unik.info/2017/06/17/scotiabank-increases-merus-labs-international-inc-msl-price-target-to-c1-65-updated-updated-updated.html.
About Merus Labs International
Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.
What are top analysts saying about Merus Labs International Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merus Labs International Inc and related companies.